Lamond David 4

What Happened
David Lamond, a director of Quince Therapeutics, was granted a derivative award covering 29,423 shares (reported at $0.00) on January 2, 2026. The award is a stock option grant issued in lieu of his 2026 outside director cash retainer.

Key Details

• Transaction date: 2026-01-02; Form 4 filed: 2026-01-21 (appears to be filed late versus the typical 2-business-day requirement).
• Reported amount/price on form: 29,423 shares at $0.00 (reported as a derivative award).
• Vesting: Shares subject to the option vest in equal quarterly installments over one year (per footnote).
• Reason: Reporting person elected options instead of the annual director cash retainer under the company’s Outside Director Compensation Policy.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.

Context
This was a compensation-related option grant (an award), not an open-market purchase or sale. Such grants are routine for non-employee directors and primarily reflect company compensation practices rather than an immediate buying or selling signal. The reported filing date suggests the Form 4 was submitted well after the transaction date; late filings can occur for administrative reasons but are subject to SEC reporting rules.